Membrane type-1 matrix metalloproteinase (MT1-MMP) expressed on the tumor cell surface activates pro-MMP-2 and pro-MMP-13 to exacerbate the malignancy, suggesting its suitability as a target molecule for diagnosis by in vivo molecular imaging. Thus, we prepared radiolabeled anti-MT1-MMP monoclonal antibody (mAb) as a novel radiolabeled probe for detecting MT1-MMP in vivo and evaluated its usefulness in breast tumor-bearing rodents. Tc-anti-MT1-MMP mAb was prepared using HYNIC as a bifunctional chelating agent and immunoreactivity was evaluated by flow cytometry. MT1-MMP expression in breast carcinoma cells (rat: Walker-256 and MRMT-1, mouse: FM3A) was measured by Western blotting. In vivo biodistribution was examined for 48 h using tumor-implanted rodents followed by estimation of radiation absorbed by a standard quantitation platform Organ Level Internal Dose Assessment (OLINDA). 
Effective methods for detecting malignant tumors in the early phase before any obvious progression has occurred permits optimal conditions for successful therapy. 1, 2) Nuclear medical techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) are non-invasive and have the potential to provide sensitive diagnoses. Both techniques detect radiation emitted from a radiolabeled probe targeted to a biological molecule relevant to tumor malignancy.
Matrix metalloproteinases (MMPs) play important roles in tumor growth, invasion and metastasis by degrading extracellular matrix components. 3) MMPs are classified as secreted MMPs or membrane-associated MMPs (MT-MMPs) based on their structure. 4) Among MT-MMPs, MT1-MMP activates pro-MMP-2 and pro-MMP-13 on the cell surface especially at lamellipodia, the migration front of cells. 5) Therefore, MT1-MMP has a close relationship with tumor malignancy. 6, 7) As a target molecule of a radiolabeled probe, it is important to be localized at the site of malignancy in order to obtain clear images that can be readily compared or fused to anatomical information. In cases where target molecules are secreted to the surrounding tissues or bodily fluids including blood, a fall of signal to noise ratio in images is inevitable. MT1-MMP is a good candidate target as expression of MT1-MMP remains localized in tumor tissues 4) and increases in the early phase of exacerbation. 8) Further, since the amino acid sequences of MT1-MMP protein are well preserved among species including mouse, rat, rabbit and human, 9) results obtained in experiments using rodents and MT1-MMP probes may provide important information for clinical applications. Thus, MT1-MMP is a potential target for imaging and diagnosing malignant tumors at early phases. Among all types of tumors, breast cancer remains a predominant cause of death from cancer in women despite advances in the treatment, especially in cases where distant metastases occur. 10) This motivated us to select breast cancer as a target disease for investigation of the MT1-MMP probe.
To the best of our knowledge, there have been no reports on the development of an MT1-MMP imaging agent for in vivo nuclear medical imaging. Therefore, in this study, we prepared Tc-99m-labeled anti-MT1-MMP monoclonal antibody and evaluated its usefulness through biodistribution studies using three kinds of rodent models bearing breast tumor allografts.
MATERIALS AND METHODS

Preparation of 99m
Tc-Anti-MT1-MMP mAb All chemicals used in this study were commercial products of the highest purity.
99m Tc-pertechnetate was eluted in saline solution on a daily basis from 99 Mo99m Tc generators (Ultra-Techne Kow ® , FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan). Succinimidyl hydrazinopyridine-3-carboxylate (HYNIC-NHS) was synthesized following the procedure reported previously.
11) Anti-MT1-MMP mAb (113-5B7, Daiichi Fine Chemical Co., Ltd., Toyama, Japan), a purified mouse monoclonal antibody to an oligopeptide (residues 319 to 333, numbered from the signal peptide) of human MT1-MMP, was used for experiments after further purification on a HiTrap rProtein A column (17-5080-01, GE Healthcare, U.K.). HYNIC-NHS (25 ml, 5 mg/ml) in dry N,N-dimethylformamide (DMF) was added to anti-MT1-MMP mAb solu-tion in 0.15 M borate buffer (pH 8.5, 2 mg/400 ml). After gentle stirring with protection from light for 2 h at room temperature, size-exclusion filtration with a diafiltration membrane (Amicon Ultra 4 (MWCO 30000), Millipore Co., Billerica, MA, U.S.A.) using 0.01 M citrate buffer (pH 5.2) was performed to obtain HYNIC-anti-MT1-MMP mAb. The protein concentration of the purified solution was determined by the bicinchoninate (BCA) method. 12) An equal volume of 99m Tc-(tricine) 2 (530Ϯ18 MBq), prepared by the method of Larsen et al., 13) was added to a solution of HYNIC-anti-MT1-MMP mAb (1 ml, 1 mg/ml) in 0.01 M citrate buffer (pH 5.2). After 3 h at room temperature, size-exclusion filtration with a PD-10 column using 0.05 M phosphate buffered saline (PBS) (pH 7.0) was performed to obtain the 99m Tc-anti-MT1-MMP mAb. Radiochemical purity of 99m Tc-anti-MT1-MMP mAb, evaluated by another size-exclusion filtration (PD-10 column), was more than 92%. Radiochemical yield was 29.9Ϯ7.5%. Mouse immunoglobulin G 3 (IgG 3 ), kappa mAb (ab18392, Abcam, Cambridge, U.K.) was radiolabeled in a similar way as a negative control for biodistribution studies.
Immunoreactivity of HYNIC-Anti-MT1-MMP mAb Antibodies (50 mg/ml, 100 ml; anti-MT1-MMP mAb, HYNIC-anti-MT1-MMP mAb or negative control IgG 3 (sc-3880, Santa Cruz Biotechnology, California, U.S.A.)) were added to mouse macrophage cells (RAW264.7, 2ϫ10 6 cells) and incubated in 0.01 M PBS (pH 7.4, 100 ml) for 30 min on ice. After washing with 0.01 M PBS, Alexa Fluor ® 488 goat anti-mouse IgG antibody (A-11001, Molecular Probes, Eugene, OR, U.S.A.) (10 mg/ml, 100 ml) was added for 30 min on ice. Fluorescence levels were measured using a flow cytometer (Becton Dickinson Inc., Franklin Lakes, NJ, U.S.A.). Data were analyzed using BD CellQuest Pro (BD Biosciences, San Jose, CA, U.S.A.) and a figure was calculated by the following equation: median fluorescence intensity of anti-MT1-MMP mAb or HYNIC-anti-MT1-MMP mAb divided by the median fluorescence intensity of negative control IgG. This was used as an index of immunoreactivity of anti-MT1-MMP mAb and HYNIC-anti-MT1-MMP mAb.
In Vitro Stability of 99m Tc-Anti-MT1-MMP mAb in Rodent Plasma 99m Tc-Anti-MT1-MMP mAb (30 ml) was added to rat (nϭ4) or mouse (nϭ3) plasma (270 ml) collected from female Sprague-Dawley (SD) rats or female C3H/He mice. Plasma samples were incubated at 37°C for 48 h. After incubation, 50 to 100 ml aliquots of samples were drawn and radioactivity was analyzed by size-exclusion chromatography with a PD-10 column using 0.05 M PBS (pH 7.0).
Preparation of Tumor-Bearing Animals Female SD rats (8 weeks old) and female C3H/He mice (5 weeks old), supplied by Japan SLC, Inc. (Hamamatsu, Japan), were housed under a 12-h light/12-h dark cycle and given free access to food and water. The animal experiments in this study were conducted in accordance with institutional guidelines and approved by the Kyoto University Animal Care Committee, Japan.
Rat breast carcinoma cells (Walker-256 and MRMT-1) and mouse breast carcinoma cells (FM3A) were supplied by the Cell Resource Center for Biomedical Research, Tohoku University and Health Science Research Resources Bank (HSRRB) (Osaka, Japan). Cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO 2 and 95% air.
Walker-256 and MRMT-1 cells were suspended in 0.01 M PBS (pH 7.4) followed by subcutaneous inoculation into the right hind flank of rats (10 6 cells/100 ml PBS/rat). FM3A cells were suspended in PBS followed by subcutaneous inoculation into the right hind leg of mice (5ϫ10 6 cells/100 ml PBS/mouse). Tumor volume was estimated by [(length)ϫ (width) 2 ]/2 14) over a 10-to 14-d tumor growth period. The average size of the tumors was 860Ϯ960 mm 3 , 790Ϯ 280 mm 3 and 230Ϯ170 mm 3 for Walker-256, MRMT-1 and FM3A, respectively, on the day before the biodistribution studies.
Western Blotting Cell lysates were prepared from Walker-256, MRMT-1 and FM3A cells by homogenization in passive lysis buffer (E194A, Promega, WI, U.S.A.) containing protease inhibitor (P8340, Sigma Aldrich Co., MO, U.S.A.). Protein content of the lysates was determined by the BCA method and 5.0 mg of protein/lane was subjected to electrophoresis on 5-20% sodium dodecyl sulfate (SDS)-polyacrylamide gels followed by transfer to polyvinylidene difluoride membranes. After blocking with Blocking One (03953-95, Nacalai Tesque, Inc., Kyoto, Japan), membranes were incubated with anti-MT1-MMP antibody followed by horseradish peroxidase-conjugated goat anti-mouse IgG 3 antibody. Bands were visualized by ECL plus Western Blotting Detection System (RPN2132, GE Healthcare, U.K.) with a Luminocapture instrument (BIO-RAD Laboratories, Osaka, Japan). Immunoblotting for b-actin was used as a protein loading control.
In Vivo Biodistribution Study Animals were divided into 5 groups (nϭ3-4 each) for 5 time points with approximately equal distribution of tumor sizes on the day before the study. Animals were fasted for 6 h before administration of radiopharmaceutical. At 1, 3, 6, 24, and 48 h after intravenous administration of 99m Tc-anti-MT1-MMP mAb (3.4Ϯ 0.9 MBq, 50 mg/200 ml PBS for rats, 50 mg/100 ml PBS for mice), animals were euthanized. The blood, heart, lung, liver, kidney, stomach, intestine, spleen, pancreas, brain, muscle and tumor were excised, weighed and counted for radioactivity with a NaI well-type scintillation counter (1470 WIZ-ARD, PerkinElmer Japan Co., Osaka, Japan). In addition, biodistribution of 99m Tc-negative control mAb was evaluated in MRMT-1 implanted rats in a similar way.
Radiation Absorbed Dose For estimating radiation absorbed doses, source organ residence times were determined by calculating the area under non-decay-corrected timeactivity curves generated for each organ using averaged biodistribution data. Projected radiation absorbed doses for humans were made by assuming that the metabolism rates and pharmacokinetics of 99m Tc-anti-MT1-MMP mAb in humans and rodents are equivalent, as previously reported. 15) Absorbed doses and effective dose were estimated with a standard quantitation platform Organ Level Internal Dose Assessment (OLINDA; Vanderbilt University). 16) 
RESULTS
In Vitro Studies Indices of immunoreactivity evaluated by flow cytometry analyses were 5.83Ϯ3.05 and 6.13Ϯ2.73 for the HYNIC-anti-MT1-MMP mAb and anti-MT1-MMP mAb, respectively. This showed that the HYNIC-anti-MT1-MMP mAb retained 93% immunoreactivity of the anti-MT1-MMP mAb (Fig. 1) . Forty-eight hours after initiation of incubation in rat and mouse plasmas at 37°C, more than 92% of 99m Tc-anti-MT1-MMP mAb remained in an unchanged form.
Western Blotting Cell lysates were subjected to Western blot analysis to examine the quantities of MT1-MMP (Fig.  2) . Expression of both the pro-(63 kDa) and active-(58 kDa) forms of MT1-MMP protein was detected in Walker-256, MRMT-1 and FM3A cells. When normalized to the level of b-actin protein, as represented in Fig. 2B , similar expression levels were confirmed.
In Vivo Biodistribution Studies Results of in vivo biodistribution studies are summarized in Table 1 (Walker-256 and MRMT-1) and Table 2 (FM3A). In tumors, radioactivity increased in a time-dependent manner and at 24 h postinjection, 3 to 5 times higher accumulations were achieved than those at 1 h. Values in % dose/g at 1 and 24 h post-injection were 0.41Ϯ0.15 and 2.04Ϯ0.65 in Walker-256, 0.44Ϯ 0.12 and 1.42Ϯ0.08 in MRMT-1, and 2.63Ϯ0.59 and 15.00Ϯ0.48 in FM3A, respectively. Radioactivity in the kidneys was rather high among organs in all three tumor animal models. Values in % dose/g in the kidneys were 3.23Ϯ0.21 1274 Vol. 32, No. 7 Immunoreactivities of anti-MT1-MMP mAb and HYNIC-anti-MT1-MMP mAb were evaluated with the median fluorescence intensity ratio compared to negative control mouse IgG 3 . Fig. 3 . The values were 0.66Ϯ0.05 at 24 h and 0.81Ϯ0.09 at 48 h post-injection. The time-course of 99m Tc-anti-MT1-MMP mAb was significantly higher than that of the 99m Tc-negative control mAb by two factor factorial ANOVA assay (pϽ0.0001).
Radiation Absorbed Dose Radiation absorbed doses (mSv/MBq) were estimated using data of biodistribution studies with 99m Tc-anti-MT1-MMP mAb (Table 3 ). The highest radiation dose was to the kidneys, followed by the liver, the intestine and the spleen. The effective dose was 4.4 to 5.0 mSv/MBq.
DISCUSSION
We prepared 99m Tc-anti-MT1-MMP mAb with a sustained immunoreactivity comparable to anti-MT1-MMP mAb and high radiochemical purity, and evaluated its usefulness through biodistribution studies using breast tumor-implanted rodents. The effectiveness of 99m Tc-anti-MT1-MMP mAb for detecting breast tumors expressing MT1-MMP, that is 'malignant tumors', was demonstrated since radioactivity in tumors and T/B and T/M ratios increased with time after administration of 99m Tc-anti-MT1-MMP mAb in all three tumor models. T/B ratios of 99m Tc-anti-MT1-MMP mAb were significantly higher than those of the 99m Tc-negative control mAb, indicating the specificity of 99m Tc-anti-MT1-MMP mAb toward MT1-MMP. The moderate accumulation of 99m Tc-negative control mAb in tumors could be due to the enhanced permeability and retention (EPR) effect, which is characterized by enhanced permeability of tumor vasculatures and little lymphatic recovery. 17) Importantly, other tissues including the stomach showed a concomitant decrease a) Tissue radioactivity is expressed as % injected dose per gram. Each value represents the mean (ϮS.D.) for three (1 h) and four (3, 6, 24, 48 h) animals. b) Expressed as % injected dose. c) Calculated using summated radioactivity of four animals. in radioactivity over time. In addition, the biodistribution results exhibiting high accumulation in tumors also indicated the suitability of this antibody for radioimmunotherapy. Together, this suggests that the radiolabeled antibody is a promising probe for in vivo nuclear medical imaging, such as single photon emission computed tomography (SPECT), for future diagnoses of breast tumors. Although further investigations are needed for more sensitive detection, it should be emphasized that this is the first report of development of an in vivo probe targeted to MT1-MMP. Also, the development of such an imaging agent provides a strong tool for clarification of the roles of MT1-MMP on tumors in vivo, which may lead to development of a novel pharmaceutical.
In the present study, technetium-99m was used to label anti-MT1-MMP mAb because of its optimal characteristics for in vivo imaging in clinical settings. This then led to the selection of HYNIC as a bifunctional chelating agent since it has high stability by coordination with Tc-99m and two molecules of tricine. 11) As expected, 99m Tc-anti-MT1-MMP mAb was stable in plasma. Furthermore, the low radioactivity detected in the stomach indicated the in vivo stability of 99m Tcanti-MT1-MMP mAb against dissociation of Tc-99m from HYNIC and oxygenation to 99m Tc pertechnetate. If dissociation had occurred, 99m Tc pertechnetate would have been taken up by the epithelial cells that line the mucosal surface of the stomach via the sodium iodide symporter system 18, 19) and the radioactivity detected would have been much higher. The high stability of the radioligand was essential for further evaluation.
Relatively slow washout of radioactivity from the blood might be a drawback for the imaging ability of 99m Tc-anti-MT1-MMP mAb. Previous researchers reported that this could be overcome by fragmentation of the antibody or synthesis of small-molecule derivatives. 20, 21) In addition, moderate radioactivities in the kidneys, liver and spleen were observed in biodistribution studies that were not due to MT1-MMP expression. 4) However, these radioactivities might not affect the imaging quality of breast tumors. To estimate the effective dose of the 99m Tc-anti-MT1-MMP mAb, which is an estimate of the stochastic effect that a non-uniform radiation dose has on a human, the OLINDA estimation gave a maximum value of 5.0 mSv/MBq. This value is similar to the average effective dose in nuclear medicine, 22) indicating that the use of 99m Tc-anti-MT1-MMP mAb may be acceptable for in vivo imaging in humans.
Several MMP imaging probes have been developed for detecting states of MMP-dependent diseases such as cancer, atherosclerosis, stroke, and other pathophysiologies. Among them, radiolabeled broad-spectrum MMP inhibitors (MPIs) have been mostly investigated during in vitro and in vivo evaluations. 23, 24) Some of these radiolabeled MPIs exhibited promising pharmacodynamics partly due to their low molecular weight. However, these small molecular probes mainly recognize soluble MMPs including MMP-2, -3, -9, and -13, while our 99m Tc-anti-MT1-MMP mAb recognizes a membrane-bound MMP, MT1-MMP. As a target molecule of a radiolabeled probe, it is important to be localized at the site of malignancy in order to obtain clear images that can be readily compared to anatomical information. Background levels can become elevated in cases where target molecules are secreted to the surrounding tissues or bodily fluids including blood. Therefore, it may be advantageous to utilize MT1-MMP rather than soluble MMPs as a target molecule for detecting cancer malignancy. In addition, the use of a monoclonal antibody and/or an antibody derivative as a fundamental part of radiolabeled probe is significantly superior to radiolabeled MPIs for strict targeting to a specific MMP.
In this study, three breast tumor cell lines, MRMT-1, Walker 256 and FM3A, from two different species were used in order to evaluate the prevalence of the radiolabeled probe. MRMT-1 is a rat mammary gland carcinoma cell line generally used for studies of bone pain, 25) where bones inoculated with these cells showed infiltration of bone marrow spaces by malignant tumors. 26) Walker 256 is also a rat breast carcinoma cell line used in a variety of cancer studies. As previously reported in a histological study, 27) these cells show several ultrastructural features that typically designate malignancy. FM3A is a murine mammary carcinoma cell line especially used in studies on hypoxia in tumors, 28) where cells showed high radioresistance. 29) Therefore, all these cell lines give rise to malignant tumors and, as expected, the expression of MT1-MMP protein was comparable in each. Similar accumulations of radioactivity in tumors were found in the biodistribution experiments.
It is known that MT1-MMP is subject to recycling.
30)
MT1-MMP is produced inside the cell by cleavage of the pro-domain of pro-MT1-MMP by furin, transited to the cell membrane, dimerized, followed by complex formation with TIMP-2 to activate pro-MMP2, and finally internalized into the cell. Dimerization of MT1-MMPs occurs by interaction of the hemopexin-like domains, a region between the transmembrane domain and catalytic domain, of two separate molecules of MT1-MMP. 31) The epitope of the antibody used in this study was in the hemopexin-like domain so that reactions between the antibody and MT1-MMP, and between two molecules of MT1-MMP, could potentially compete for each other on the cell surface. Although it was not elucidated whether this competition would affect the results, providing that it does occur in vivo like pertuzumab, 32) imaging efficiency may be further improved using an alternative antibody whose epitope is in a different domain of MT1-MMP.
The amino acid sequences of MT1-MMP protein are well preserved among species, including mouse, rat, rabbit and human.
9) The antibody used here was an anti-human MT1-MMP mouse monoclonal antibody IgG 3 , though results were obtained in a rodent animal model in this study. In addition, this antibody is suited for detection of human MT1-MMP by preliminary Western blot analysis using lysates from human breast cancer cells (MDA-MB-231) (data not shown). Thus, the preferable outcomes reported for rodents might be easily translated to a clinical situation, after the antibody is optimally humanized to lose immunogenicity and endure metabolism in the body.
MT1-MMP is reported to experience shedding by other proteases on the cell surface leading to soluble MT1-MMP secreted into the blood. 33) Although a variety of forms of soluble MT1-MMP have been reported due to differences in the position of cleavage, 34) it is unclear whether the antibody used in this study would react with soluble MT1-MMP in the blood. Since the biodistribution experiments of 99m Tc-anti-MT1-MMP mAb showed a normal, or rather fast, clearance from the body, soluble MT1-MMP in the blood might not af-fect the results.
CONCLUSION
99m Tc-anti-MT1-MMP mAb accumulated in malignant tumors of all three animal models with a low effective dose, while radioactivity disappeared in non-targeted organs. The results suggest that the 99m Tc-anti-MT1-MMP mAb is a promising probe for in vivo nuclear medical imaging for future diagnosis of breast tumors.
